Enveric Biosciences, a forward-thinking biotechnology company specializing in neuroplastogenic treatments for neuropsychiatric disorders, has announced preclinical results that underscore the potential of their novel drug candidate, EB-003. These findings, detailed in a recent press release, highlight the drug’s oral bioavailability and significant brain exposure, positioning it as a promising treatment for severe mental health conditions.
